Literature DB >> 9525685

Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.

J M Binley1, X Jin, Y Huang, L Zhang, Y Cao, D D Ho, J P Moore.   

Abstract

Long-term nonprogressor AD-18 has been infected with human immunodeficiency virus type 1 (HIV-1) for at least 16 years. During the past 5 years, he has had undetectable levels of plasma viremia, and HIV-1 cannot be isolated from him. Sequencing of proviral DNA indicates that the only HIV-1 sequences that can be identified in AD-18 have gross defects in the p17-encoding regions of the gag gene (Y. Huang, L. Zhang, and D. D. Ho, Virology 240:36-49, 1998). However, AD-18 has strong, sustained antibody responses to several HIV-1 antigens, including p17. Cytotoxic T-lymphocyte responses to Env and Gag antigens have gradually diminished over the past 4 years, at a time when the titers of antibodies to the same proteins have remained stable. We discuss what these observations might mean for the generation and maintenance of immunological memory.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525685      PMCID: PMC109859     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.

Authors:  W Cavert; D W Notermans; K Staskus; S W Wietgrefe; M Zupancic; K Gebhard; K Henry; Z Q Zhang; R Mills; H McDade; C M Schuwirth; J Goudsmit; S A Danner; A T Haase
Journal:  Science       Date:  1997-05-09       Impact factor: 47.728

2.  Serological detection of attenuated HIV-1 variants with nef gene deletions.

Authors:  A L Greenway; J Mills; D Rhodes; N J Deacon; D A McPhee
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

3.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells.

Authors:  M F Bachmann; T M Kündig; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  1994-10-15       Impact factor: 5.422

5.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Huang; L Zhang; D D Ho
Journal:  Virology       Date:  1998-01-05       Impact factor: 3.616

7.  Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  L Zhang; Y Huang; H Yuan; S Tuttleton; D D Ho
Journal:  Virology       Date:  1997-02-17       Impact factor: 3.616

8.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

Authors:  M Markowitz; M Vesanen; K Tenner-Racz; Y Cao; J M Binley; A Talal; A Hurley; X Jin; M R Chaudhry; M Yaman; S Frankel; M Heath-Chiozzi; J M Leonard; J P Moore; P Racz; D F Nixon; D D Ho; X J
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

10.  The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy.

Authors:  K Tenner-Racz; H J Stellbrink; J van Lunzen; C Schneider; J P Jacobs; B Raschdorff; G Grosschupff; R M Steinman; P Racz
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

View more
  10 in total

1.  Evidence for a cytopathogenicity determinant in HIV-1 Vpr.

Authors:  Mohan Somasundaran; Mark Sharkey; Beda Brichacek; Katherine Luzuriaga; Michael Emerman; John L Sullivan; Mario Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

2.  A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect.

Authors:  Hendrik Huthoff; Atze T Das; Monique Vink; Bep Klaver; Fokla Zorgdrager; Marion Cornelissen; Ben Berkhout
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.

Authors:  M Dalod; M Dupuis; J C Deschemin; D Sicard; D Salmon; J F Delfraissy; A Venet; M Sinet; J G Guillet
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection.

Authors:  L Alexander; E Weiskopf; T C Greenough; N C Gaddis; M R Auerbach; M H Malim; S J O'Brien; B D Walker; J L Sullivan; R C Desrosiers
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1.

Authors:  W B Dyer; G S Ogg; M A Demoitie; X Jin; A F Geczy; S L Rowland-Jones; A J McMichael; D F Nixon; J S Sullivan
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease.

Authors:  Hong Zhang; Federico Hoffmann; Jun He; Xiang He; Chipepo Kankasa; John T West; Charles D Mitchell; Ruth M Ruprecht; Guillermo Orti; Charles Wood
Journal:  Retrovirology       Date:  2006-10-20       Impact factor: 4.602

9.  Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

Authors:  Paul R Gorry; Dale A McPhee; Erin Verity; Wayne B Dyer; Steven L Wesselingh; Jennifer Learmont; John S Sullivan; Michael Roche; John J Zaunders; Dana Gabuzda; Suzanne M Crowe; John Mills; Sharon R Lewin; Bruce J Brew; Anthony L Cunningham; Melissa J Churchill
Journal:  Retrovirology       Date:  2007-09-23       Impact factor: 4.602

10.  Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus.

Authors:  Melissa J Churchill; Lisa Chiavaroli; Steven L Wesselingh; Paul R Gorry
Journal:  Retrovirology       Date:  2007-07-01       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.